Novavax, Inc. (NVAX)
NVAXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$8.51
-0.2650 (-3.02%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.41bn
- P/E
- –
- EPS, last 4 quarters
- $-0.4600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.20 to $13.39
- Average volume
- –
- Previous close
- $8.78
Analysts
5 coveringHold3 buy, 0 hold, 2 sell
Targets a year out average $13.60, +59.8% from here
Earnings
next estimate $0.6000Next report
Dec 2025
+116.7%
Mar 2026
+76.0%
Jun 2026
+11.1%
Sep 2026
+48.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $147.14m | $139.51m | $56.70m | $68.30m |
| Gross profit | $125.03m | $108.82m | $42.45m | $44.81m |
| Operating income | $14.23m | -$15.43m | -$54.91m | -$31.28m |
| Net income | $17.53m | -$9.49m | -$53.39m | -$31.38m |
Last four quarters: revenue $411.65m, margin -18.6%, free cash flow -$243.25m
News
8 latest- Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItZacks · 4 days ago
- Novavax Consensus Price Target Raised 13.54% to $14.39Fintel · 6 days ago
- NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs DeclineZacks · Nov 6, 2026
- Novavax Q3 Earnings Call HighlightsMarketBeat · Nov 6, 2026
- Novavax, Inc. Reports Third Quarter 2026 Financial ResultsFintel · Nov 5, 2026
- Novavax (NVAX) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- Novavax (NVAX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 5, 2026
- Novavax, Inc. Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine TrialFintel · Oct 30, 2026
The company
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, targeted and capital-efficient R&D innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid, R21/Matrix-M), Matrix technology and R&D assets.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- novavax.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.